الفهرس 
B-Cell chronic lymphocytic leukemia
Immunological aspects and complications:Only 14 pages are availabe for public view
 |  | from | 170 |  |  |
| | | from | 170 | | |
Abstract
Summary
Chronic lymphocytic leukemia (CLL) is one of most malignancy in our world with average prevalence of 3.9 new patients per 100,000 populations per year; male to female ratio is approximately 2:1 with median age at diagnosis 60 years old. It is associated with infection due to hypogammaglobulinemia, autoimmune phenomena and secondary malignancies.
B-CLL originates in bone marrow and affects B lymphocytes which develop in lymph node producing antibodies fighting infection, B cells CLL grow abnormally and accumulate in bone marrow and blood, where they crowd out healthy blood cells.
CD52 is glycosyl-phosphatidyl-inositol loosely anchored glycoprotein of 29 KDa. It is present approximately in all normal blood cells and leukemic cells but higher level on lymphocytes and malignant B cells, and also it is present on surface of neoplastic lymphocytes in patients with CLL, low grade Lymphoma and most T – cell malignancy. It also expressed in some patients with myeloid, monocytic and acute lymphoblastic leukemia.
Soluble CD52 can shed from CLL cells in vitro and in vivo (chemoimmunotherapy). However the correlation between soluble CD52, the disease activity and response to therapy is not thoroughly investigated.